Based on the Aquestive Therapeutics Inc stock forecast from 6 analysts, the average analyst target price for Aquestive Therapeutics Inc is USD 9.93 over the next 12 months. Aquestive Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aquestive Therapeutics Inc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Aquestive Therapeutics Inc’s stock price was USD 3.07. Aquestive Therapeutics Inc’s stock price has changed by -2.23% over the past week, -14.25% over the past month and +16.73% over the last year.
No recent analyst target price found for Aquestive Therapeutics Inc
No recent average analyst rating found for Aquestive Therapeutics Inc
Company Overview Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey. Read Less
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenor...Read More
Frequently Asked Questions About Aquestive Therapeutics Inc (AQST) Stock
Based on ratings from 6 analysts Aquestive Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 14 buy, sell and hold ratings.
Unfortunately we do not have enough data on AQST's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for AQST is USD 9.93 over the next 12 months. The maximum analyst target price is USD 17 while the minimum anlayst target price is USD 7.
Unfortunately we do not have enough data on AQST's stock to indicate if its overvalued.
The last closing price of AQST's stock was USD 3.07.
The most recent market capitalization for AQST is USD 0.28B.
Based on targets from 6 analysts, the average taret price for AQST is projected at USD 9.93 over the next 12 months.
This means that AQST's stock price may go up by +223.41% over the next 12 months.
We can't find any ETFs which contains Aquestive Therapeutics Inc's stock.
As per our most recent records Aquestive Therapeutics Inc has 135 Employees.
Aquestive Therapeutics Inc's registered address is 30 Technology Drive, Warren, NJ, United States, 07059.
You can get more information about it from Aquestive Therapeutics Inc's website at https://www.aquestive.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Aquestive Therapeutics Inc (AQST) Stock
Based on ratings from 6 analysts Aquestive Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 14 buy, sell and hold ratings.
Unfortunately we do not have enough data on AQST's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for AQST is USD 9.93 over the next 12 months. The maximum analyst target price is USD 17 while the minimum anlayst target price is USD 7.
Unfortunately we do not have enough data on AQST's stock to indicate if its overvalued.
The last closing price of AQST's stock was USD 3.07.
The most recent market capitalization for AQST is USD 0.28B.
Based on targets from 6 analysts, the average taret price for AQST is projected at USD 9.93 over the next 12 months.
This means that AQST's stock price may go up by +223.41% over the next 12 months.
We can't find any ETFs which contains Aquestive Therapeutics Inc's stock.
As per our most recent records Aquestive Therapeutics Inc has 135 Employees.
Aquestive Therapeutics Inc's registered address is 30 Technology Drive, Warren, NJ, United States, 07059.
You can get more information about it from Aquestive Therapeutics Inc's website at https://www.aquestive.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AQST !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
